Comparative study of intrathecal dexmedetomidine with intrathecal magnesium sulfate used as adjuvants to bupivacaine

Background: No drug, used as adjuvant to spinal bupivacaine, has yet been identified that specifically inhibits nociception without its associated side-effects. Aims: This prospective randomized double-blind study was conducted to evaluate the onset and duration of sensory and motor block as well as perioperative analgesia and adverse effects of dexmedetomidine and magnesium sulfate given intrathecally with 0.5% hyperbaric bupivacaine for spinal anesthesia. Materials and Methods: A total of 90 patients classified as American Society of Anesthesiologists status I and II scheduled for lower abdominal and lower limb procedures were prospectively studied. Patients were randomly allocated to receive intrathecally either 15 mg hyperbaric bupivacaine plus 0.1 ml (10 μg) dexmedetomidine (group D, n=30) or 15 mg hyperbaric bupivacaine plus 0.1 ml (50 mg) magnesium sulfate (group M, n=30) or 15 mg hyperbaric bupivacaine plus 0.1 ml saline (group C, n=30) as control. The onset time to reach peak sensory and motor level, the regression time for sensory and motor block, hemodynamic changes and side-effects were recorded. Statistical Analysis Used: All statistical analyses were performed using INSTAT for windows. Continuous variables were tested for normal distribution by the Kolmogorov-Smirnov test. Data was expressed as either mean and standard deviation or numbers and percentages. Continuous covariates (age, body mass index and height) were compared using analysis of variance (ANOVA). For the times to reach T10 dermatomes, Bromage 3 scale and the regression of the sensory block to S1 dermatome and Bromage scale 0, one-way ANOVA was used to compare the means. The level of significance used was P<0.05. Results: The onset times to reach T10 dermatome and to reach peak sensory level as well as onset time to reach modified Bromage 3 motor block were significantly different in the three groups. The onset time to reach peak sensory and motor level was shorter in group D as compared with the control group C, and it was significantly prolonged in group M. We also found that patients in group D had significant longer sensory and motor block times than patients in group M, which was greater than in the control group C. Conclusion: It was found that onset of anesthesia was rapid and of prolonged duration in the dexmedetomidine group (D). However, in the magnesium sulfate group (M), although onset of block was delayed, the duration was significantly prolonged as compared with the control group (C), but to a lesser degree than in the dexmedetomidine group (D). The groups were similar with respect to hemodynamic variables and there were no significant side-effects in either of the groups.

[1]  Ayman Qatawneh,et al.  Effect of Adding Dexmedetomidine versus Fentanyl to Intrathecal Bupivacaine on Spinal Block Characteristics in Gynecological Procedures: A Double Blind Controlled Study , 2009 .

[2]  M. M. Murshidi,et al.  Effect of dexmedetomidine added to spinal bupivacaine for urological procedures. , 2009, Saudi medical journal.

[3]  S. Palmisani,et al.  Combined intrathecal and epidural magnesium sulfate supplementation of spinal anesthesia to reduce post‐operative analgesic requirements: a prospective, randomized, double‐blind, controlled trial in patients undergoing major orthopedic surgery , 2007, Acta anaesthesiologica Scandinavica.

[4]  A. Baraka,et al.  Effect of low‐dose dexmedetomidine or clonidine on the characteristics of bupivacaine spinal block , 2006, Acta anaesthesiologica Scandinavica.

[5]  G. Işık,et al.  The effect of adding intrathecal magnesium sulphate to bupivacaine–fentanyl spinal anaesthesia , 2005, Acta anaesthesiologica Scandinavica.

[6]  J. Kroin,et al.  Intrathecal Magnesium Prolongs Fentanyl Analgesia: A Prospective, Randomized, Controlled Trial , 2002, Anesthesia and analgesia.

[7]  R. Venn,et al.  Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. , 2001, British journal of anaesthesia.

[8]  Dong-Chan Kim,et al.  Magnesium Sulfate Does Not Reduce Postoperative Analgesic Requirements , 2001, Anesthesiology.

[9]  M. Hollmann,et al.  Modulation of NMDA Receptor Function by Ketamine and Magnesium: Part I , 2001, Anesthesia and analgesia.

[10]  J. Kroin,et al.  Magnesium Sulfate Potentiates Morphine Antinociception at the Spinal Level , 2000, Anesthesia and analgesia.

[11]  W. Fawcett,et al.  Magnesium: physiology and pharmacology. , 1999, British journal of anaesthesia.

[12]  Keiji Ishizaki,et al.  The effect of intrathecal magnesium sulphate on nociception in rat acute pain models , 1999, Anaesthesia.

[13]  M. Tramèr,et al.  Role of Magnesium Sulfate in Postoperative Analgesia , 1996, Anesthesiology.

[14]  S. Pockett,et al.  Spinal Cord Synaptic Plasticity and Chronic Pain , 1995, Anesthesia and analgesia.

[15]  F. Lublin,et al.  Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double‐blind, placebo‐controlled trial , 1994, Neurology.

[16]  Clifford J. Woolf,et al.  The induction and maintenance of central sensitization is dependent on N-methyl-d-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states , 1991, Pain.

[17]  E. Kalso,et al.  Spinal Antinociception by Dexmedetomidine, a Highly Selective α2-Adrenergic Agonist , 1991 .

[18]  M. Maze,et al.  Alpha-2B adrenoceptor activation inhibits a nociceptive response in the spinal cord of the neonatal rat , 1990 .

[19]  T. Archer,et al.  Antinociceptive Effects and Spinal Cord Tissue Concentrations after Intrathecal Injection of Guanfacine or Clonidine into Rats , 1987, Anesthesia and analgesia.

[20]  T. Yaksh,et al.  Studies in the primate on the analgetic effects associated with intrathecal actions of opiates, alpha-adrenergic agonists and baclofen. , 1981, Anesthesiology.

[21]  P. Bromage A Comparison of the Hydrochloride and Carbon Dioxide Salts of Lidocaine and Prilocaine in Epidural Analgesia , 1965, Acta anaesthesiologica Scandinavica. Supplementum.

[22]  U. Schambra,et al.  alpha 2-Adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha 2-adrenergic receptor subtypes at four distinct levels. , 1995, Brain research. Molecular brain research.